On June 24, we are inviting selected investors to a closed-door session on Glucowear, a next-generation pain-free, real-time glucose monitoring device designed to transform diabetes care into a more lifestyle-driven, user-empowered experience by Afon Technology Ltd.

The gathering will include a live Q&A session with the senior leadership and technical team (clinical, engineering, regulatory, and commercial), alongside existing investors, providing an opportunity for prospective investors to conduct due diligence and gain deeper insight into the company's clinical progress, regulatory pathway, manufacturing strategy and commercialization plans.

The company is raising a £7.5M Series A at a £26M pre-money valuation to support final trials, regulatory approvals, manufacturing scale-up and team expansion.

This is a 2-hour live video call starting at 7am PST, designed for focused due diligence and direct engagement with the founding team.